Agios signs US$147.5 M License Deal with Alnylam’s RNAi therapeutic for Polycythemia Vera
By Shweta Gupta
Pharma Deals Review: Vol 2023 Issue 8 (Table of Contents)
Published: 22 Aug-2023
DOI: 10.3833/pdr.v2023.i8.2801 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its rare disease portfolio, Agios Pharmaceuticals has entered into an exclusive worldwide license agreement with Alnylam Pharmaceuticals for the development and commercialisation of RNA interference (siRNA) therapeutics for the treatment of the rare haematologic disease, polycythemia vera (PV)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS